Ontario becomes first province to provide public funding of Tresiba for adults with diabetes mellitus

Novo Nordisk

21 September 2018 - Manitoba to reimburse Tresiba following Ontario listing.

Novo Nordisk Canada announces that Ontario will now reimburse Tresiba (insulin degludec injection) FlexTouch pre-filled pen in both 100 units/mL and 200 units/mL doses, as a general benefit for people living with Type 2 and Type 1 diabetes. Tresiba is an ultra-long-acting basal insulin, for adults with diabetes mellitus, and will now be reimbursed under the Ontario Drug Benefit program, effective 27 September 2018.

In addition, the Government of Manitoba also announced that it will reimburse Tresiba (insulin degludec injection) for both 100 units/mL and 200 units/mL doses under the Manitoba Drug Benefits and Interchangeability Formulary, effective 18 October 2018.

Read Novo Nordisk press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Listing , Canada , Ontario